Comparative Pharmacology
Head-to-head clinical analysis: ASPRUZYO SPRINKLE versus DEXILANT SOLUTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPRUZYO SPRINKLE versus DEXILANT SOLUTAB.
ASPRUZYO SPRINKLE vs DEXILANT SOLUTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASPRUZYO SPRINKLE (lacosamide) enhances slow inactivation of voltage-gated sodium channels, stabilizing neuronal membranes and inhibiting repetitive neuronal firing.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Oral: 30 mg once daily, with or without food. Sprinkle capsules can be opened and contents mixed with soft food or liquid.
30 mg orally once daily for 4-8 weeks; for non-erosive GERD, 30 mg orally once daily for 4 weeks; for erosive esophagitis, 60 mg orally once daily for up to 8 weeks; for maintenance of healed EE and relief of heartburn, 30 mg orally once daily. Administer without regard to food; dissolve tablet in water.
None Documented
None Documented
Terminal half-life is approximately 20-30 hours, allowing for once-daily dosing. Steady-state achieved within 5-7 days.
Terminal elimination half-life is approximately 1-2 hours; however, the pharmacodynamic half-life (duration of acid suppression) is prolonged due to accumulation in parietal cell canaliculi.
Primarily hepatic metabolism via CYP3A4 and CYP2C9, with <2% excreted unchanged in urine. Biliary/fecal excretion accounts for >90% of metabolites.
Renal (approx. 53% as metabolites, <2% as unchanged drug), biliary/fecal (approx. 47%).
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor